SOAT1 and familial pancreatic carcinoma: Previously, the SOAT1 inhibitor avasimibe was reported to have reliable therapeutic effect through reducing the incidence of cancers, including liver cancer, pancreatic cancer, glioma, ovarian cancer, and lung carcinoma (41, 62–65).